Sumitomo Pharma Past Earnings Performance
Past criteria checks 5/6
Sumitomo Pharma has been growing earnings at an average annual rate of 2%, while the Pharmaceuticals industry saw earnings growing at 5.8% annually. Revenues have been declining at an average rate of 7.5% per year. Sumitomo Pharma's return on equity is 27.6%, and it has net margins of 23.7%.
Key information
2.04%
Earnings growth rate
1.93%
EPS growth rate
| Pharmaceuticals Industry Growth | 3.41% |
| Revenue growth rate | -7.51% |
| Return on equity | 27.57% |
| Net Margin | 23.73% |
| Next Earnings Update | 30 Oct 2026 |
Recent past performance updates
Recent updates
Sumitomo Pharma's (TSE:4506) Attractive Earnings Are Not All Good News For Shareholders
We didn't see Sumitomo Pharma Co., Ltd.'s ( TSE:4506 ) stock surge when it reported robust earnings recently. We looked...
4506: Orphan Drug Designations Will Support Future Leukemia Pipeline Upside
Analysts now place Sumitomo Pharma's fair value estimate at ¥2,000, down from ¥2,158. The adjustment reflects updated views on revenue growth, profit margins, and the appropriate discount rate and P/E multiple for the stock.Investors Shouldn't Be Too Comfortable With Sumitomo Pharma's (TSE:4506) Earnings
Sumitomo Pharma Co., Ltd.'s ( TSE:4506 ) robust earnings report didn't manage to move the market for its stock. Our...Optimistic Investors Push Sumitomo Pharma Co., Ltd. (TSE:4506) Shares Up 26% But Growth Is Lacking
Despite an already strong run, Sumitomo Pharma Co., Ltd. ( TSE:4506 ) shares have been powering on, with a gain of 26...Is Sumitomo Pharma (TSE:4506) Using Too Much Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Investors Appear Satisfied With Sumitomo Pharma Co., Ltd.'s (TSE:4506) Prospects As Shares Rocket 38%
Despite an already strong run, Sumitomo Pharma Co., Ltd. ( TSE:4506 ) shares have been powering on, with a gain of 38...Results: Sumitomo Pharma Co., Ltd. Beat Earnings Expectations And Analysts Now Have New Forecasts
A week ago, Sumitomo Pharma Co., Ltd. ( TSE:4506 ) came out with a strong set of first-quarter numbers that could...Sumitomo Pharma Co., Ltd.'s (TSE:4506) Shares Climb 36% But Its Business Is Yet to Catch Up
Sumitomo Pharma Co., Ltd. ( TSE:4506 ) shares have continued their recent momentum with a 36% gain in the last month...Does Sumitomo Pharma (TSE:4506) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Sumitomo Pharma Co., Ltd.'s (TSE:4506) 30% Share Price Surge Not Quite Adding Up
Sumitomo Pharma Co., Ltd. ( TSE:4506 ) shares have continued their recent momentum with a 30% gain in the last month...We Believe Sumitomo Pharma's (TSE:4506) Earnings Are A Poor Guide For Its Profitability
Strong earnings weren't enough to please Sumitomo Pharma Co., Ltd.'s ( TSE:4506 ) shareholders over the last week. We...Sumitomo Pharma Co., Ltd. Just Recorded A 72% EPS Beat: Here's What Analysts Are Forecasting Next
A week ago, Sumitomo Pharma Co., Ltd. ( TSE:4506 ) came out with a strong set of full-year numbers that could...Why Investors Shouldn't Be Surprised By Sumitomo Pharma Co., Ltd.'s (TSE:4506) 26% Share Price Plunge
Sumitomo Pharma Co., Ltd. ( TSE:4506 ) shares have had a horrible month, losing 26% after a relatively good period...Is Sumitomo Pharma (TSE:4506) Using Debt In A Risky Way?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Sumitomo Pharma Co., Ltd. Just Recorded A 593% EPS Beat: Here's What Analysts Are Forecasting Next
Sumitomo Pharma Co., Ltd. ( TSE:4506 ) just released its quarterly report and things are looking bullish. Statutory...Sentiment Still Eluding Sumitomo Pharma Co., Ltd. (TSE:4506)
You may think that with a price-to-sales (or "P/S") ratio of 0.6x Sumitomo Pharma Co., Ltd. ( TSE:4506 ) is a stock...Sumitomo Pharma (TSE:4506) Has Debt But No Earnings; Should You Worry?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Is There An Opportunity With Sumitomo Pharma Co., Ltd.'s (TSE:4506) 38% Undervaluation?
Key Insights The projected fair value for Sumitomo Pharma is JP¥909 based on 2 Stage Free Cash Flow to Equity Current...There's No Escaping Sumitomo Pharma Co., Ltd.'s (TSE:4506) Muted Revenues Despite A 26% Share Price Rise
Sumitomo Pharma Co., Ltd. ( TSE:4506 ) shares have continued their recent momentum with a 26% gain in the last month...A Piece Of The Puzzle Missing From Sumitomo Pharma Co., Ltd.'s (TSE:4506) 28% Share Price Climb
Those holding Sumitomo Pharma Co., Ltd. ( TSE:4506 ) shares would be relieved that the share price has rebounded 28% in...Is Sumitomo Pharma Co., Ltd. (TSE:4506) Trading At A 34% Discount?
Key Insights Sumitomo Pharma's estimated fair value is JP¥628 based on 2 Stage Free Cash Flow to Equity Sumitomo Pharma...Market Cool On Sumitomo Pharma Co., Ltd.'s (TSE:4506) Revenues
You may think that with a price-to-sales (or "P/S") ratio of 0.5x Sumitomo Pharma Co., Ltd. ( TSE:4506 ) is a stock...Revenue & Expenses Breakdown
How Sumitomo Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 26 | 474,787 | 112,656 | 166,596 | 47,251 |
| 31 Mar 26 | 453,294 | 106,865 | 163,016 | 43,996 |
| 31 Dec 25 | 453,395 | 110,092 | 169,061 | 41,000 |
| 30 Sep 25 | 445,205 | 154,723 | 146,951 | 41,117 |
| 30 Jun 25 | 416,159 | 18,903 | 170,904 | 44,916 |
| 31 Mar 25 | 398,832 | 23,634 | 180,155 | 49,865 |
| 31 Dec 24 | 372,713 | -176,042 | 369,020 | 75,729 |
| 30 Sep 24 | 342,665 | -279,457 | 353,657 | 88,553 |
| 30 Jun 24 | 329,547 | -260,167 | 400,005 | 97,917 |
| 31 Mar 24 | 314,558 | -314,969 | 397,705 | 112,637 |
| 31 Dec 23 | 330,307 | -173,718 | 241,301 | 129,509 |
| 30 Sep 23 | 388,897 | -134,970 | 319,776 | 132,234 |
| 30 Jun 23 | 471,354 | -144,485 | 336,814 | 135,280 |
| 31 Mar 23 | 555,544 | -74,512 | 339,212 | 131,858 |
| 31 Dec 22 | 588,228 | -8,448 | 317,779 | 103,117 |
| 30 Sep 22 | 585,594 | 12,680 | 277,888 | 99,177 |
| 30 Jun 22 | 588,715 | 82,719 | 232,567 | 96,896 |
| 31 Mar 22 | 560,035 | 56,413 | 217,339 | 94,903 |
| 31 Dec 21 | 553,262 | 32,321 | 215,676 | 128,794 |
| 30 Sep 21 | 548,184 | 55,372 | 220,722 | 93,741 |
| 30 Jun 21 | 513,291 | 42,762 | 186,715 | 129,367 |
| 31 Mar 21 | 515,952 | 56,219 | 173,666 | 132,682 |
| 31 Dec 20 | 520,477 | 67,031 | 192,295 | 103,086 |
| 30 Sep 20 | 513,627 | 47,720 | 190,219 | 104,167 |
| 30 Jun 20 | 499,105 | 52,309 | 164,201 | 120,800 |
| 31 Mar 20 | 482,732 | 40,753 | 143,076 | 115,112 |
| 31 Dec 19 | 469,413 | 52,637 | 120,924 | 124,091 |
| 30 Sep 19 | 463,715 | 51,088 | 120,595 | 121,193 |
| 30 Jun 19 | 460,840 | 40,083 | 150,218 | 101,556 |
| 31 Mar 19 | 459,267 | 48,627 | 172,581 | 102,364 |
| 31 Dec 18 | 449,588 | 42,826 | 179,466 | 80,994 |
| 30 Sep 18 | 452,530 | 46,430 | 183,812 | 87,868 |
| 30 Jun 18 | 466,452 | 54,285 | 180,247 | 87,859 |
| 31 Mar 18 | 466,838 | 53,448 | 177,113 | 86,928 |
| 31 Dec 17 | 470,252 | 50,011 | 189,681 | 91,555 |
| 30 Sep 17 | 454,013 | 52,956 | 178,920 | 83,457 |
| 30 Jun 17 | 424,447 | 35,035 | 173,780 | 81,413 |
| 31 Mar 17 | 411,638 | 28,991 | 172,335 | 80,819 |
| 31 Dec 16 | 404,181 | 30,923 | 168,387 | 80,247 |
| 30 Sep 16 | 402,368 | 22,405 | 169,998 | 79,577 |
| 30 Jun 16 | 408,566 | 27,122 | 172,500 | 81,264 |
| 31 Mar 16 | 403,206 | 24,697 | 174,052 | 82,033 |
| 31 Dec 15 | 396,763 | 19,799 | 175,825 | 79,064 |
| 30 Sep 15 | 392,006 | 16,903 | 175,511 | 78,336 |
Quality Earnings: 4506 has a large one-off gain of ¥49.8B impacting its last 12 months of financial results to 30th June, 2026.
Growing Profit Margin: 4506's current net profit margins (23.7%) are higher than last year (4.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4506's earnings have grown by 2% per year over the past 5 years.
Accelerating Growth: 4506's earnings growth over the past year (496%) exceeds its 5-year average (2% per year).
Earnings vs Industry: 4506 earnings growth over the past year (496%) exceeded the Pharmaceuticals industry 13%.
Return on Equity
High ROE: 4506's Return on Equity (27.6%) is considered high.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/12 08:01 |
| End of Day Share Price | 2026/08/12 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sumitomo Pharma Co., Ltd. is covered by 17 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Atsushi Seki | Barclays |
| Koichi Mamegano | BofA Global Research |
| Hidemaru Yamaguchi | Citigroup Inc |